Reports Q2 revenue $14.7B, consensus $13.53B. Dr. Albert Bourla, Chairman and CEO of Pfizer (PFE): “Pfizer had another strong quarter of focused execution and we’re pleased with our progress in advancing our R&D pipeline, driving our commercial performance and expanding our margins. We continue to strengthen our company for the future and we’re confident in our ability to create further value for patients and our shareholders.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- Pfizer’s Long-Term Study on Ritlecitinib Offers Hope for Alopecia Areata Treatment
- Pfizer’s Phase 1 Study on Drug Interactions: Key Insights for Investors
- Pfizer’s PF-07275315 Study: A Step Forward in Drug Development
- Pfizer’s Phase 1 Study on PF-07258669: Key Insights for Investors
- Pfizer’s Xeljanz Study: A New Chapter in Juvenile Arthritis Treatment